During the past decade, Nycomed Deutschland GmbH conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Nycomed Deutschland GmbH" are "Gastroesophageal Reflux Disease" (3 trials), "Non-Erosive Reflux Disease" (2 trials), "Asthma" (1 trials), "Breakthrough Pain" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Nycomed Deutschland GmbH" in a lesser frequency.

Most popular intervention types in "Nycomed Deutschland GmbH" are "Drug" (11 trials). Other intervention types were less common.

The name of intervention was led by "Pantoprazole" (5 trials), "Daxas" (2 trials), "Ciclesonide" (1 trials), "Fentanyl" (1 trials) and "Instanyl (Intranasal Fentanyl)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nycomed Deutschland GmbH" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Nycomed Deutschland GmbH". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Nycomed Deutschland GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nycomed Deutschland GmbH, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".